Risultati della ricerca - V.R. Peddi

  • Mostra 1 - 6 risultati su 6
Raffina i risultati
  1. 1
    Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus

    Association of Clinical Events With Everolimus Exposure in Kidney Transplant Patients Receiving Low Doses of Tacrolimus di Fuad S. Shihab, Y. Qazi, S. Mulgaonkar, Kevin McCague, Dharmesh Patel, V.R. Peddi, David R. Shaffer

    Pubblicazione 2017
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  2. 2
    Interim Results from an Open-Label Study of Planned Transition from Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Cardiovascular Safety

    Interim Results from an Open-Label Study of Planned Transition from Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Cardiovascular Safety di Hélio Tedesco‐Silva, V.R. Peddi, A. Sanchez-Fructoso, Graeme R. Russ, Brad A. Marder, C. Hahn, H. Li, Alison Flynn, Sam Schulman

    Pubblicazione 2012
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  3. 3
    Open-Label Study of Planned Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft.

    Open-Label Study of Planned Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft. di Hélio Tedesco‐Silva, V.R. Peddi, A. Sanchez-Frutuoso, Brad A. Marder, Graeme R. Russ, Alison Flynn, C. Hahn, Michael A. Tortorici, Sam Schulman

    Pubblicazione 2014
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  4. 4
    Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data

    Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data di Yasir Qazi, David R. Shaffer, Bruce Kaplan, D.Y. Kim, Fu L. Luan, V.R. Peddi, Fuad S. Shihab, Stephen J. Tomlanovich, S. Yilmaz, Kevin McCague, Dharmesh Patel, S. Mulgaonkar

    Pubblicazione 2016
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  5. 5
    Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Impact On Glycemic Parameters.

    Transition From Tacrolimus to Sirolimus vs Continued Tacrolimus in Renal Allograft Recipients: Impact On Glycemic Parameters. di Fritz Diekmann, Hélio Tedesco‐Silva, V.R. Peddi, A. Sanchez-Fructoso, Brad A. Marder, G. R. Russ, Alison Flynn, C. Hahn, H. Li, Michael A. Tortorici, Sam Schulman

    Pubblicazione 2014
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  6. 6
    Calcineurin-Inhibitor-Free Immunosuppression Based on the JAK Inhibitor CP-690,550: A Pilot Study in De Novo Kidney Allograft Recipients

    Calcineurin-Inhibitor-Free Immunosuppression Based on the JAK Inhibitor CP-690,550: A Pilot Study in De Novo Kidney Allograft Recipients di Stéphan Busque, Joseph R. Leventhal, Daniel C. Brennan, Steven Steinberg, Göran B. Klintmalm, T. Shah, S. Mulgaonkar, Jonathan S. Bromberg, F. Vincenti, Sundaram Hariharan, Douglas P. Slakey, V.R. Peddi, Rosemary A. Fisher, Nervin Lawendy, C. Wang, Gordon Chun‐Kau Chan

    Pubblicazione 2009
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: